Autor(es): Alferes, Daniela ; Coelho, Inês ; Ferreira, Hugo ; Chuva, Teresa ; Paiva, Ana ; Chacim, Sérgio ; Mariz, José Mário ; Maximino Costa, José
Data: 2024
Origem: Portuguese Kidney Journal (PKJ)
Assunto(s): Acute Kidney Injury/chemically induced; Acute Kidney Injury/etiology; Receptors, Antigen, T‐Cell/therapeutic use; Chimeric Antigen
Introduction: Chimeric antigen receptor (CAR) T‐cell therapy is an effective new treatment for hematologic malignan‐ cies. In this study, we aimed to characterize the acute kidney injury (AKI) and electrolyte disorders among adults with refractory and relapsed haematological malignancies treated with CAR‐T therapy and explore clinical outcomes. Methods: A retrospective, observational study was performed. Adult patients who received anti‐CD19 CAR‐T therapy between January 2019 and July 2022 were screened for inclusion. Results: Among 41 patients receiving CAR T‐cell therapy, cytokine release syndrome and neurotoxicity rates occurred in 65.9% and 19.5%, respectively. AKI occurred in 6 patients (14.6%): 4 had stage 1 AKI and 2 developed stage 2 AKI, all re‐ lated to decreased kidney perfusion. Electrolyte abnormalities occurred in 65.9% and most of them were clinically mild. Conclusion: In this study, the incidence of AKI was low, with a complete resolution in most cases by the end of follow‐up. Electrolyte abnormalities were common among recipients of CAR‐T, although of low severity.
